Enlivex Therapeutics Ltd. (ENLV), Monday announced a positive interim data from a Phase I/II clinical trial of Allocetra in patients with severe knee osteoarthritis patients indicated for knee replacement surgery.
The company said it tried a single Allocetra injection to the knee as a potential last resort alternative for pain resolution and knee functionality in lieu of knee-replacement surgery.
A total of nine patients have been enrolled and treated with a single Allocetra injection to the knee and evaluated for at least three months following treatment.
At the three-month follow up, out of the nine patients enrolled, eight of them reported an improvement in their knee pain compared to their baseline pain prior to treatment, while 33 of the patients reported complete pain relief.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.